CLAIMS:

1. A compound represented by formula (I):

$$\begin{array}{c|c}
X & 0 & NHR^1 \\
X & 0 & NHR^1 \\
Y & N = C - N
\end{array}$$

$$\begin{array}{c|c}
X & 0 & NHR^1 \\
N = C - N
\end{array}$$

$$\begin{array}{c|c}
R^3 & (I) \\
R^4 & (I)
\end{array}$$

wherein

5

10

15

X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;

Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or -N(R²)₂;

R¹ is hydrogen or lower alkyl;

each R^2 is, independently, $-R^7$, $-(CH_2)_m$ -OR⁸, $-(CH_2)_m$ -NR⁷R¹⁰, $-(CH_2)_n(CHOR^8)(CHOR^8)_n$ -CH₂OR⁸, $-(CH_2CH_2O)_m$ -R⁸, $-(CH_2CH_2O)_m$ -CH₂CH₂NR⁷R¹⁰, $-(CH_2)_n$ -C(=O)NR⁷R¹⁰, $-(CH_2)_n$ -Z_g-R⁷, $-(CH_2)_m$ -NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, $-(CH_2)_n$ -CO₂R⁷, or

$$-(CH_2)_n - Q R^7$$

R³ and R⁴ are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl-lower alkyl, (halophenyl)-lower alkyl, lower-(alkylphenylalkyl), lower alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or pyridyl-lower alkyl, with the proviso that at least one of R³ and R⁴ is a group represented by formula (A):

$$-(C(R^{L})_{2})_{0}-X-(C(R^{L})_{2})_{p}-Q OH$$

$$Q-Q (R^{6})_{4}$$
(A)

wherein

5

10

15

20

each R^L is, independently, -R⁷, -(CH₂)_n-OR⁸, -O-(CH₂)_m-OR⁸,

 $-(CH_2)_n-NR^7R^{10}$, $-O-(CH_2)_m-NR^7R^{10}$, $-(CH_2)_n(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

-O-(CH₂)_m(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -(CH₂CH₂O)_m-R⁸,

 $-O-(CH_2CH_2O)_m-R^8$, $-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$,

 $-O-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-(CH_2)_n-C(=O)NR^7R^{10}$,

 $-O-(CH_2)_m-C(=O)NR^7R^{10}$, $-(CH_2)_n-(Z)_g-R^7$, $-O-(CH_2)_m-(Z)_g-R^7$,

-(CH₂)_n-NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸,

 $-O-(CH_2)_m-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

-(CH₂)_n-CO₂R⁷, -O-(CH₂)_m-CO₂R⁷, -OSO₃H, -O-glucuronide, -O-glucose, or

$$-O\left(CH_2\right)_{m} \xrightarrow{O} R^7$$
 or
$$-(CH_2)_{n} \xrightarrow{O} R^7$$

each x is, independently, O, NR⁷, C=O, CHOH, C=N-R⁶, or represents a single bond;

each o is, independently, an integer from 0 to 10;

each p is, independently, an integer from 0 to 10;

with the proviso that (a) the sum of o and p in each contiguous chain is from 1 to 10 when x is O, NR⁷, C=O, or C=N-R⁶ or (b) that the sum of o and p in each contiguous chain is from 4 to 10 when x represents a single bond;

each R^6 is, independently, $-R^7$, -OH, $-OR^{11}$, $-N(R^7)_2$, $-(CH_2)_m$ - OR^8 ,

 $-O-(CH_2)_m-OR^8$, $-(CH_2)_n-NR^7R^{10}$, $-O-(CH_2)_m-NR^7R^{10}$,

 $-(CH_2)_n(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-O-(CH_2)_m(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

 $-(CH_2CH_2O)_m-R^8$, $-O-(CH_2CH_2O)_m-R^8$, $-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$,

 $-O-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-(CH_2)_n-C(=O)NR^7R^{10}$,

-O-(CH₂)_m-C(=O)NR⁷R¹⁰,-(CH₂)_n-(Z)_g-R⁷,-O-(CH₂)_m-(Z)_g-R⁷,
-(CH₂)_n-NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸,
-O-(CH₂)_m-NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸,
-(CH₂)_n-CO₂R⁷, -O-(CH₂)_m-CO₂R⁷, -OSO₃H, -O-glucuronide, -O-glucose,

$$-O\left(CH_2\right)_{m}$$
 O
 R^7
or
 $-(CH_2)_{n}$
 O
 R^7

wherein when two R⁶ are -OR¹¹ and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two R⁶ may be bonded together to form a methylenedioxy group;

10

15

20

each R⁷ is, independently, hydrogen or lower alkyl; each R⁸ is, independently, hydrogen, lower alkyl, -C(=O)-R¹¹, glucuronide, 2-tetrahydropyranyl, or

$$O \longrightarrow OR^{11}$$

$$O \longrightarrow OCOR^{11}$$

$$OCOR^{11}$$

$$OCOR^{11}$$

each R⁹ is, independently, -CO₂R⁷, -CON(R⁷)₂, -SO₂CH₃, or -C(=O)R⁷; each R¹⁰ is, independently, -H, -SO₂CH₃, -CO₂R⁷, -C(=O)NR⁷R⁹, -C(=O)R⁷, or -CH₂-(CHOH)_n-CH₂OH; each Z is, independently, CHOH, C(=O), CHNR⁷R¹⁰, C=NR¹⁰, or NR¹⁰; each R¹¹ is, independently, lower alkyl; each g is, independently, an integer from 1 to 6; each m is, independently, an integer from 1 to 7; each n is, independently, an integer from 0 to 7; each Q is, independently, C-R⁵, C-R⁶, or a nitrogen atom, wherein at most three Q in a ring are nitrogen atoms;

or a pharmaceutically acceptable salt thereof, and inclusive of all enantiomers, diastereomers, and racemic mixtures thereof.

- 2. The compound of Claim 1, wherein Y is -NH₂.
- 5 3. The compound of Claim 2, wherein R² is hydrogen.
 - 4. The compound of Claim 3, wherein R¹ is hydrogen.
 - 5. The compound of Claim 4, wherein X is chlorine.
 - 6. The compound of Claim 5, wherein R³ is hydrogen.
 - 7. The compound of Claim 6, wherein each R^L is hydrogen.
 - 8. The compound of Claim 7, wherein o is 4.
 - 9. The compound of Claim 8, wherein p is 0.
 - 10. The compound of Claim 9, wherein x represents a single bond.
 - 11. The compound of Claim 10, wherein each R⁶ is hydrogen.
 - 12. The compound of Claim 11, wherein at most one Q is a nitrogen atom.
- 15 13. The compound of Claim 12, wherein no Q is a nitrogen atom.
 - 14. The compound of Claim 1, wherein

X is halogen;

10

Y is $-N(R^7)_2$;

R¹ is hydrogen or C₁-C₃ alkyl; and

20 R^2 is $-R^7$, $-(CH_2)_m - OR^7$, or $-(CH_2)_n - CO_2R^7$;

R³ is a group represented by formula (A); and R⁴ is hydrogen, a group represented by formula (A), or lower alkyl;

15. The compound of Claim 14, wherein

X is chloro or bromo;

Y is $-N(R^7)_2$;

5

10

15

R² is hydrogen or C₁-C₃ alkyl;

at most three R⁶ are other than hydrogen as defined above;

at most three RL are other than hydrogen as defined above; and

at most 2 Q are nitrogen atoms.

- 16. The compound of Claim 15, wherein Y is -NH₂.
 - 17. The compound of Claim 16, wherein R⁴ is hydrogen; at most one R^L is other than hydrogen as defined above; at most two R⁶ are other than hydrogen as defined above; and at most 1 Q is a nitrogen atom.
 - 18. The compound of Claim 17, wherein x is O, NR⁷, C=O, CHOH, or C=N-R⁶.
 - 19. The compound of Claim 17, wherein x represents a single bond.
 - 20. The compound of Claim 1, wherein x is O, NR⁷, C=O, CHOH, or C=N-R⁶.
 - 21. The compound of Claim 1, wherein x represents a single bond.
- 20 22. The compound of Claim 1, wherein each R⁶ is hydrogen.
 - 23. The compound of Claim 1, wherein at most two R⁶ are other than hydrogen as defined in Claim 1.

- 24. The compound of Claim 1, wherein one R⁶ is other than hydrogen as defined in Claim 1.
 - 25. The compound of Claim 1, wherein one R⁶ is -OH.
 - 26. The compound of Claim 1, wherein each R^L is hydrogen.
- 5 27. The compound of Claim 1, wherein at most two R^L are other than hydrogen as defined in Claim 1.
 - 28. The compound of Claim 1, wherein one R^L is other than hydrogen as defined in Claim 1.
- 29. The compound of Claim 1, wherein x represents a single bond and the sum of o and p is 4 to 6.
 - 30. The compound of Claim 1, which is represented by the formula

$$\begin{array}{c|c} Cl & NH & OH \\ NH & NH & NH \end{array}$$

- 31. The compound of Claim 30, which is in the form of a pharmaceutically acceptable salt.
 - 32. The compound of Claim 31, which is in the form of a hydrochloride salt.
- 15 33. The compound of Claim 1, which is represented by the formula

$$\begin{array}{c|c} Cl & N & NH \\ NH & NH & NH \\ \end{array}$$

- 34. The compound of Claim 33, which is in the form of a pharmaceutically acceptable salt.
 - 35. The compound of Claim 34, which is in the form of a hydrochloride salt.
 - 36. The compound of Claim 1, which is represented by the formula

$$\begin{array}{c|c} O & NH \\ \hline \\ Cl & NH \\ NH_2N & NH_2 \end{array}$$

- 5 37. The compound of Claim 36, which is in the form of a pharmaceutically acceptable salt.
 - 38. The compound of Claim 37, which is in the form of a hydrochloride salt.
 - 39. The compound of Claim 1, which is represented by the formula

$$\begin{array}{c|c} Cl & NH & NH \\ NH & NH \end{array}$$

- 40. The compound of Claim 39, which is in the form of a pharmaceutically acceptable salt.
 - 41. The compound of Claim 40, which is in the form of a hydrochloride salt.
 - 42. The compound of Claim 1, which is represented by the formula

$$Cl$$
 N
 NH
 NH
 NH
 NH
 NH

- 5 43. The compound of Claim 42, which is in the form of a pharmaceutically acceptable salt.
 - 44. The compound of Claim 43, which is in the form of a hydrochloride salt.
 - 45. The compound of Claim 1, which is represented by the formula

$$\begin{array}{c|c} O & NH & HO \\ \hline \\ NH & NH \\ \hline \\ NH_2 & NH_2 \\ \end{array}$$

- 46. The compound of Claim 45, which is in the form of a pharmaceutically acceptable salt.
 - 47. The compound of Claim 46, which is in the form of a hydrochloride salt.
- 48. The compound of Claim 1, which is in the form of a pharmaceutically acceptable salt.
 - 49. A pharmaceutical composition, comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
- 50. A method of promoting hydration of mucosal surfaces, comprising:
 administering an effective amount of the compound of Claim 1 to a mucosal surface of
 a subject.
 - 51. A method of restoring mucosal defense, comprising: topically administering an effective amount of the compound of Claim 1 to a mucosal surface of a subject in need thereof.
 - 52. A method of blocking sodium channels, comprising: contacting sodium channels with an effective amount of the compound of Claim 1.
 - 53. A method of treating chronic bronchitis, comprising: administering an effective amount of the compound of Claim 1 to a subject in need thereof.
- 54. A method of treating cystic fibrosis, comprising:

 administering an effective amount of the compound of Claim 1 to a subject in need thereof.

- 55. A method of treating sinusitis, comprising:
 administering an effective amount of the compound of Claim 1 to a subject in need thereof.
- 56. A method of treating vaginal dryness, comprising:
 administering an effective amount of the compound of Claim 1 to the vaginal tract of a subject in need thereof.
 - 57. A method of treating dry eye, comprising: administering an effective amount of the compound of Claim 1 to the eye of a subject in need thereof.
- 58. A method of promoting ocular hydration, comprising:administering an effective amount of the compound of Claim 1 to the eye of a subject.
 - 59. A method of promoting corneal hydration, comprising: administering an effective amount of the compound of Claim 1 to the eye of a subject.
 - 60. A method of promoting mucus clearance in mucosal surfaces, comprising: administering an effective amount of the compound of Claim 1 to a mucosal surface of a subject.

- 61. A method of treating Sjogren's disease, comprising:
 administering an effective amount of the compound of Claim 1 to a subject in need thereof.
- 62. A method of treating distal intestinal obstruction syndrome, comprising: administering an effective amount of the compound of Claim 1 to a subject in need thereof.

- 63. A method of treating dry skin, comprising:
 administering an effective amount of the compound of Claim 1 to the skin of a subject in need thereof.
- 64. A method of treating esophagitis, comprising:

 administering an effective amount of the compound of Claim 1 to a subject in need thereof.
 - 65. A method of treating dry mouth (xerostomia), comprising: administering an effective amount of the compound of Claim 1 to the mouth of a subject in need thereof.
- 66. A method of treating nasal dehydration, comprising:

 administering an effective amount of the compound of Claim 1 to the nasal passages of a subject in need thereof.
 - 67. The method of Claim 66, wherein the nasal dehydration is brought on by administering dry oxygen to the subject.
 - 68. A method of preventing ventilator-induced pneumonia, comprising: administering an effective amount of the compound of Claim 1 to a subject on a ventilator.

- 69. A method of treating asthma, comprising:

 administering an effective amount of the compound of Claim 1 to a subject in need
 thereof.
 - 70. A method of treating primary ciliary dyskinesia, comprising:
 administering an effective amount of the compound of Claim 1 to a subject in need thereof.

71. A method of treating otitis media, comprising:
administering an effective amount of the compound of Claim 1 to a subject in need thereof.

72. A method of inducing sputum for diagnostic purposes, comprising:
administering an effective amount of the compound of Claim 1 to a subject in need thereof.

5

10

- 73. A method of treating chronic obstructive pulmonary disease, comprising: administering an effective amount of the compound of Claim 1 to a subject in need thereof.
 - 74. A method of treating emphysema, comprising: administering an effective amount of the compound of Claim 1 to a subject in need thereof.
- 75. A method of treating pneumonia, comprising:
 administering an effective amount of the compound of Claim 1 to a subject in need thereof.
 - 76. A method of treating constipation, comprising: administering an effective amount of the compound of Claim 1 to a subject in need thereof.
 - 77. The method of Claim 76, wherein the compound is administered orally or via a suppository or enema.
 - 78. A method of treating chronic diverticulitis, comprising: administering an effective amount of the compound of Claim 1 to a subject in need thereof.

79. The present invention also provides a method of treating rhinosinusitis, comprising:

administering an effective amount of the compound of Claim 1 to a subject in need thereof.

5 80. A composition, comprising: the compound of Claim 1; and a P2Y2 inhibitor.

10

81. A composition, comprising: the compound of Claim 1; and a bronchodilator.